Immunoprecise Antibodies Ltd (IPA) — Net Asset Quality Index
Immunoprecise Antibodies Ltd (IPA) has a Net Asset Quality Index of 53.2% as of April 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $44.44 Million minus total liabilities of $20.82 Million yields net assets of $23.63 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check Immunoprecise Antibodies Ltd (IPA) asset resilience to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Immunoprecise Antibodies Ltd Net Asset Quality Index Over Time (1997–2025)
This chart shows how Immunoprecise Antibodies Ltd's Net Asset Quality Index has evolved across 29 annual periods from 1997 to 2025. As of April 2025, the index stands at 53.2%, representing net assets of $23.63 Million against total assets of $44.44 Million USD. See Immunoprecise Antibodies Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Immunoprecise Antibodies Ltd (1997–2025)
The table below presents the year-by-year Net Asset Quality Index for Immunoprecise Antibodies Ltd from 1997 to 2025, covering 29 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market cap of Immunoprecise Antibodies Ltd.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 53.2% | $23.63 Million | $44.44 Million | $20.82 Million | ▼ -3.4 pp |
| 2024 | 56.5% | $33.92 Million | $59.99 Million | $26.07 Million | ▼ -17.7 pp |
| 2023 | 74.3% | $57.80 Million | $77.81 Million | $20.01 Million | ▼ -6.2 pp |
| 2022 | 80.5% | $75.28 Million | $93.49 Million | $18.21 Million | ▼ -4.5 pp |
| 2021 | 85.0% | $56.92 Million | $66.96 Million | $10.04 Million | ▲ +29.7 pp |
| 2020 | 55.3% | $15.09 Million | $27.26 Million | $12.18 Million | ▼ -8.4 pp |
| 2019 | 63.7% | $18.07 Million | $28.35 Million | $10.28 Million | ▲ +12.1 pp |
| 2018 | 51.7% | $12.70 Million | $24.58 Million | $11.87 Million | ▼ -27.0 pp |
| 2017 | 78.7% | $3.09 Million | $3.93 Million | $836.91K | ▲ +12.9 pp |
| 2016 | 65.8% | $908.26K | $1.38 Million | $472.15K | ▲ +517.9 pp |
| 2015 | -452.2% | $-208.52K | $46.12K | $254.64K | ▼ -338.9 pp |
| 2014 | -113.3% | $-161.21K | $142.29K | $303.50K | ▲ +318.2 pp |
| 2013 | -431.5% | $-215.66K | $49.97K | $265.63K | ▼ -302.9 pp |
| 2012 | -128.6% | $-119.89K | $93.22K | $213.10K | ▼ -187.6 pp |
| 2011 | 59.0% | $158.40K | $268.61K | $110.21K | ▼ -39.3 pp |
| 2010 | 98.2% | $5.43 Million | $5.53 Million | $97.87K | ▲ +0.4 pp |
| 2009 | 97.8% | $6.78 Million | $6.93 Million | $150.84K | ▼ -1.4 pp |
| 2008 | 99.3% | $5.12 Million | $5.16 Million | $37.46K | ▲ +6.4 pp |
| 2007 | 92.9% | $5.43 Million | $5.84 Million | $413.69K | ▼ -3.7 pp |
| 2006 | 96.6% | $3.91 Million | $4.05 Million | $138.62K | ▼ -2.3 pp |
| 2005 | 98.9% | $4.23 Million | $4.28 Million | $47.18K | ▲ +2.4 pp |
| 2004 | 96.5% | $1.39 Million | $1.44 Million | $49.92K | ▼ -0.2 pp |
| 2003 | 96.7% | $867.54K | $897.07K | $29.53K | ▲ +18.1 pp |
| 2002 | 78.7% | $691.56K | $879.28K | $187.72K | ▲ +56.0 pp |
| 2001 | 22.6% | $262.24K | $1.16 Million | $896.75K | ▼ -74.9 pp |
| 2000 | 97.5% | $396.53K | $406.64K | $10.11K | ▼ -0.3 pp |
| 1999 | 97.8% | $1.62 Million | $1.66 Million | $35.78K | ▲ +0.1 pp |
| 1998 | 97.7% | $2.86 Million | $2.93 Million | $67.39K | ▲ +4.1 pp |
| 1997 | 93.6% | $3.63 Million | $3.88 Million | $250.04K | — |